Seattle Genetics Planning to Launch 12 More Cancer Drugs

One of the Seattle and Puget Sound area’s drug companies is Seattle Genetics (Nasdaq: SGEN). Their first drug is already on the market. They are working hard to increase its use, and they’re planning to introduce 12 more into their product pipeline as well as hire another 100 people. They’ve hired an average of 100 people per year since they started up. They are the leading making of antibody conjugate drugs.

Their first drug, Adcetris, approved for use by the FDA in 2011, is now available in 47 countries. Its partner Takeda Pharmaceutical sells it outside of the United States and Canada. They are working to get it approved for various types of lymphomas. It’s in Phase 3 for previously untreated or newly diagnosed Hodgkin lymphoma. They’ve got another drug they hope to enter Phase 3 trials late this year for acute myeloid leukemia, but so far that’s known just as 33A.

They’re based in Seattle, but also have an office in Switzerland.

Clay B. Siegall started Seattle Genetics in 1998 to make a difference in the lives of cancer patients. His basic plan is to use antibody-based therapies. He explains what those are in his video on YouTube. He is the Chief Executive Officer and a member of the board of directors. Current chemotherapy drugs are potent poisons. They kill all cells that are dividing. That includes both cancer cells and regular cells that are dividing. They do help some cancer patients, but at the cost of killing many ordinary cells, further harming the patient.

He came up with the idea of using antibodies because they identify and collect on cancer cells, not ordinary cells. These antibodies don’t themselves kill cancer cells, but what if they carried something that did? That is the kind of drug Siegall and Seattle Genetics is developing. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute for six years. He also worked for the National Cancer Institute of the National Institutes for Health. He earned his B.S. in Zoology from the University of Maryland and his Ph.D in Genetics from George Washington University. He’s on the Board of Directors of the Washington Biotechnical and Biomedical Association.

Seattle Genetics is Planning to Add 12 ADCS in its Drug Pipeline

Following a recent tour by Joe Biden, the Vice President of the U.S., the expanding cancer research community of the Puget Sound area is in the glare of publicity. Seattle Genetics is a cancer drug company that has been instrumental in propelling the war against cancer in the region. The company is on a mission of widening the use of its first commercialized drug and expands its drug pipeline with exceptional drugs. The Bothell-based firm is preparing for another hiring spree.

ADCETRIS exposed to more cancer-treatment settings

Seattle Genetics is experimenting ADCETRIS, its only commercialized antibody-based drug in new cancer-treatment scenarios. Currently, it is being experimented in over 70 trials against different forms of lymphomas. To be specific, the firm is conducting an advanced clinical trial that leverages ADCETRIS to treat formerly untreatable and recently diagnosed Hodgkin Lymphoma.

ADCETRIS performance

ADCETRIS specializes in fighting lymphomas. In 2015, the medication garnered $226 million in sales for the U.S. and Canadian markets combined. According to the firm, the sales in those nations for 2016 will range from $255 to 275 million. Takeda Pharmaceutical is in charge of marketing and selling the drug outside Canada and the United States. Seattle is developing 12 antibody-based cancer medications excluding ADCETRIS.

Who is Dr. Clay Siegall?

Dr. Siegall is a qualified and experienced scientist, who has taken the fight against cancer to a top-notch level. Dr. Siegall is one of the founding partners and current CEO of Seattle Genetics, a leading biotechnology champion that develops antibody-based medications for fighting cancerous cells. Under his guidance, the firm commercialized ADCETRIS in 2011, and it is on the verge of diversifying its portfolio of antibody-based drugs.

Dr. Siegall has overseen Seattle’s capital-raising initiatives, enabling the firm to secure over $675 million via private and public funding. Its IPO in 2001 also contributed a big chunk of its growth capital. Dr. Siegall has held numerous powerful positions at the top research institutes and facilities in the healthcare industry such as National Institutes of Health, Bristol-Myers Squibb Pharmaceutical Research Institute, and National Cancer Institute. He has written over 70 publications and registered 15 patents. He holds an undergrad in Zoology and a Ph.D. in Genetics.

Learn more about Siegall:

http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145